Results 21 to 30 of about 1,136,503 (270)

Linear psoriasis unresponsive to multiple biological therapies (anti-TNF, anti-IL-12/23, and anti-IL-23): a case report [PDF]

Anais Brasileiros de Dermatologia
Sonia Romero-Romero, Maribel Iglesias-Sancho, Albert Martin-Poch, Montserrat Salleras-Redonnet   +3 more
doaj   +2 more sources

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

Frontiers in Immunology
Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease.
James G. Krueger, Kilian Eyerich, Kilian Eyerich, Vijay K. Kuchroo, Christopher T. Ritchlin, Maria T. Abreu, M. Merle Elloso, Anne Fourie, Steven Fakharzadeh, Jonathan P. Sherlock, Jonathan P. Sherlock, Ya-Wen Yang, Daniel J. Cua, Iain B. McInnes   +13 more
doaj   +2 more sources

Is anti‐IL‐17 faster and anti‐IL‐23 better for psoriasis patients after adalimumab failure?

JEADV Clinical Practice, 2023
Xiaojun Shi, Keke Li, Chen Li
doaj   +2 more sources

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis

Clinics, 2021
Monoclonal antibodies or fusion proteins, defined as biological drugs, have modified the natural history of numerous immune-mediated disorders, allowing the development of therapies aimed at blocking the pathophysiological pathways of the disease ...
Fernando Valenzuela, Rodrigo Flores
doaj   +1 more source

Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study

Journal of dermatological treatment (Print), 2023
Palmoplantar psoriasis is a subtype of psoriasis that occurs in 12-26% of patients during the natural history of the disease. Limited data are available regarding the use of biologics in psoriasis with the involvement of palms or soles.
L. Ibba, L. Gargiulo, A. Alfano, R. Cascio Ingurgio, A. Narcisi, A. Costanzo, M. Valenti   +6 more
semanticscholar   +1 more source

Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients

Journal of the European Academy of Dermatology and Venereology, 2023
Many national guidelines at the European level recommend first‐line therapy based on the anti‐TNF‐alpha adalimumab for treatment of psoriasis and psoriatic arthritis, mainly for economic reasons.
L. Mastorino, S. Susca, C. Cariti, N. Sliquini, A. Verrone, E. Stroppiana, M. Ortoncelli, P. Dapavo, S. Ribero, P. Quaglino   +9 more
semanticscholar   +1 more source

P328 In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel Disease

Journal of Crohn's & Colitis, 2022
Despite advances in the treatment of inflammatory bowel diseases (IBD), fewer than, 40% of patients reach clinical remission, suggesting that improved response rates may require targeting of multiple pathogenic pathways through combination therapy.
J. Perrigoue, L. Muniz-Bongers, L. Ong, Y. Chen, L. Chang, K. Ngo, A. Stojmirović, C. O'Brien, M. Germinaro, R. Rao, M. Vetter, J. Towne   +11 more
semanticscholar   +1 more source

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

European Journal of Dermatology, 2021
Guselkumab, a subcutaneously administered fully human IgG1λ monoclonal antibody that selectively inhibits the p19 subunit of interleukin 23, is approved in both the USA and the EU for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Chiricozzi A., Costanzo A., Fargnoli M. C., Malagoli P., Piaserico S., Amerio P., Argenziano G., Balato N., Bardazzi F., Bianchi L., Carrera C. G., Conti A., Dapavo P., De Simone C., Loconsole F., Lo Schiavo A., Malara G., Musumeci M. L., Parodi A., Peris K., Prignano F., Rongioletti F., Talamonti M., Potenza C.   +23 more
openaire   +11 more sources

Ustekinumab

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response.
Murat Borlu
doaj   +1 more source

Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL‐17, anti‐12/23 and/or anti IL‐23: Preliminary data of a real‐life 16‐week retrospective study

Dermatologic Therapy, 2020
Up until now, real‐life experiences on the efficacy of risankizumab in patients who had previously failed anti‐IL17, anti‐IL12/23 or anti‐IL23 inhibitor are not reported.
M. Megna, G. Fabbrocini, A. Ruggiero, E. Cinelli   +3 more
semanticscholar   +1 more source